Researchers conduct study to identify common genetic architecture of PCOS
PCOS is the most common endocrine disorder found in reproductive-age women, and is a major cause of infertility and type 2 diabetes. The source of the disease is
Genprex has received a notice of allowance from the Canadian Intellectual Property Office (CIPO) for a patent related to the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either programmed cell death protein 1 (PD-1) or PD-L1 antibodies to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
The preliminary safety analysis of the ARCHES trial appears consistent with the safety profile of XTANDI in previous clinical trials in castration-resistant prostate cancer (CRPC). Detailed results will